<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950467</url>
  </required_header>
  <id_info>
    <org_study_id>15-17825</org_study_id>
    <nct_id>NCT02950467</nct_id>
  </id_info>
  <brief_title>Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors</brief_title>
  <official_title>Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua Woolley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heffter Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RiverStyx Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Usona Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stupski Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is
      a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label mixed-methods pilot study of an individual oral psilocybin drug
      session combined with ten sessions of an evidence-based, manualized brief group psychotherapy
      for existential distress in palliative care patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events as assessed by NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0</measure>
    <time_frame>Enrollment to 3-month follow up, about 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject recruitment and retention</measure>
    <time_frame>Duration of study, about 24 months</time_frame>
    <description>Two therapy groups of at least 4 subjects each will complete the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Demoralization Scale-II at endpoint</measure>
    <time_frame>Baseline and endpoint (6 weeks duration)</time_frame>
    <description>Demoralization measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Demoralization Scale-II at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Demoralization measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Inventory of Complicated Grief at endpoint</measure>
    <time_frame>Baseline and endpoint (6 weeks duration)</time_frame>
    <description>Complicated Grief measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Inventory of Complicated Grief at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Complicated Grief measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Center for Epidemiologic Studies Depression Scale-Revised at endpoint</measure>
    <time_frame>Baseline and endpoint (6 weeks duration)</time_frame>
    <description>Depression measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Center for Epidemiologic Studies Depression Scale-Revised at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Depression measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in slope of Group Questionnaire pre-psilocybin and post-psilocybin</measure>
    <time_frame>Weekly from Baseline to Endpoint (Week 5)</time_frame>
    <description>Group cohesion measure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in PTSD Checklist 5 at endpoint</measure>
    <time_frame>Baseline and endpoint (6 weeks duration)</time_frame>
    <description>PTSD symptom measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in PTSD Checklist 5 at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>PTSD symptom measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in State-Trait Anxiety Inventory at endpoint</measure>
    <time_frame>Baseline and endpoint (6 weeks duration)</time_frame>
    <description>Anxiety measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in State-Trait Anxiety Inventory at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Anxiety measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in HIV and Abuse Related Shame Inventory at endpoint</measure>
    <time_frame>Baseline and endpoint (6 weeks duration)</time_frame>
    <description>Shame measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in HIV and Abuse Related Shame Inventory at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Shame measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Experiences in Closer Relationships-M16 at endpoint</measure>
    <time_frame>Baseline and endpoint (6 weeks duration)</time_frame>
    <description>Measure of attachment anxiety and avoidance</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Experiences in Closer Relationships-M16 at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Measure of attachment anxiety and avoidance</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in McGill Quality of Life Questionnaired-Revised Short at endpoint</measure>
    <time_frame>Baseline and endpoint (Week 5)</time_frame>
    <description>Quality of life measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in McGill Quality of Life Questionnaired-Revised Short at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Quality of life measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Antiretroviral Medication Adherence Scale at endpoint</measure>
    <time_frame>Baseline and endpoint (Week 5)</time_frame>
    <description>Medication adherence</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Antiretroviral Medication Adherence Scale at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Medication adherence</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Distress</condition>
  <condition>Depression</condition>
  <condition>Grief</condition>
  <arm_group>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>One individual oral psilocybin treatment session</description>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
    <other_name>4-phosphoryloxy-N,N-dimethyltryptamine</other_name>
    <other_name>Indocybin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Modified brief Supportive Expressive Group Therapy</intervention_name>
    <description>Ten sessions of twice-weekly manualized group therapy</description>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterion:

          -  Older women who are long-term AIDS survivors and suffer from moderate-to-severe
             demoralization.

        Exclusion Criteria:

          -  A physical, neurological or cognitive condition that makes participating in the study
             unsafe or unfeasible.

          -  Regular psychotropic medication use.

          -  Personal or family history of serious mental illness.

          -  Severe depression requiring immediate standard-of-care treatment.

          -  Exclusion by the clinical judgment of the study investigators.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Cis-gendered women</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Woolley, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Anderson, MD,MSc</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Joshua Woolley</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>Demoralization</keyword>
  <keyword>Psilocybin</keyword>
  <keyword>Group therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
    <mesh_term>N,N-Dimethyltryptamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Final protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02950467/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Final ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02950467/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: ICF for Cohorts 2 and 3</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02950467/ICF_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Pre-modifications related to enrollment exceptions</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02950467/Prot_SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

